NVO
✅ Novo Nordisk’s Wegovy has FDA and EMA approval for obesity and overweight treatment.
📈 The company has shown sustained growth in profitability, with increasing EBITDA and positive earnings per share.
💰 It maintains a stable dividend history with a payout close to 50%, offering investors consistent returns.
🔴 A sharp 20% stock drop occurred due to the underperformance of its new-generation obesity drug, Caris Erma.
@rankia:
“Novo Nordisk, a Danish pharmaceutical giant primarily known for its diabetes treatments, is now prominent for its star product, Wegovy, which is changing the game in obesity treatment. This medication has both FDA and EMA approval for treating obesity and overweight, and it has shown the ability to reduce patient weight by 15% to 17% after 68 weeks of treatment. The company had to recognize that its new-generation obesity drug, Caris Erma, had not had the expected success; only 22.7% of patients responded positively to the treatment when at least 25% was expected.”
Watch the exact part of the video where Rankia talks about Novo Nordisk here:
View the video on YouTube.
Read more articles by the world’s top 100 analysts on Novo Nordisk (NVO) at the following link. NVO stock.
